This post was originally published on this site The donor-derived, or allogeneic CAR T-cell therapy candidate UCARTCS1 has been administrated to the first patient in an ongoing Phase 1 trial for relapsed/refractory multiple myeloma. The study (NCT04142619), called MELANI-01, plans to enroll up to 18 adults whose multiple myeloma relapsed after prior treatment. It is…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
FDA Approves BeiGene’s Brukinsa to Treat Adults with Mantle Cell Lymphoma
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. According to BeiGene, the medication should become available to patients in the U.S. within…
Ninlaro Prolongs Progression-free Survival in Multiple Myeloma Patients Not Given ASCT, Phase 3 Trial Shows
This post was originally published on this site First-line maintenance therapy with Ninlaro (ixazomib) prolongs the time without disease progression in adults with multiple myeloma not treated with an autologous stem cell transplant, meeting its primary goal, data from a Phase 3 trial show. Ninlaro is an oral proteasome inhibitor marketed by Takeda. Proteasome inhibitors block…
UCLA Launches Fundraising Effort for New Research Center for Sarcoidosis, Other Advanced Lung Diseases
This post was originally published on this site The University of California, Los Angeles (UCLA) is launching a fundraising initiative to help improve treatment for advanced lung diseases, including sarcoidosis. The fundraising effort — called the Lung Health Research Accelerator Fund — aims to generate a total $20 million for the creation of a new…
Ovarian Cancer Risk in Fertility Assistance Rises Mainly for Women with Endometriosis, Study Suggests
This post was originally published on this site Women who require assisted reproductive technology to become mothers are not more likely to develop ovarian cancer, except for those with endometriosis, a new study suggests. The study, “Assisted reproductive technology treatment and risk of ovarian cancer—a nationwide population-based cohort study,” was published in the journal Human…
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy May Benefit Myeloma Patients, Phase 1 Trial Shows
This post was originally published on this site Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and prolong survival outcomes in multiple myeloma patients, long-term results of a Phase 1 clinical trial show. Results were published in the journal Biology of Blood and Marrow Transplantation in…
Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection
This post was originally published on this site The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas positive for Epstein-Barr virus (EBV) infection. A therapy candidate is put on a fast track by the…
Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial
This post was originally published on this site Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according to new results from a Phase 1/2a clinical trial. The latest data from part A of the trial…
More Than $850M Raised for Inflammatory Breast Cancer Research
This post was originally published on this site Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation have joined to raise more than $850,000 for research targeting innovative diagnostic tools and therapy options, and to address questions and challenges in inflammatory breast cancer. Inflammatory breast cancer is a rare but…
Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance
This post was originally published on this site Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial assessing the safety and efficacy of its immunotherapy Provenge (sipuleucel-T) for men with early-stage prostate cancer on active surveillance, the company announced. The open-label ProVent trial (NCT03686683) included more than 450 participants…
FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The designation facilitates the development and review process of therapies that can treat severe conditions and…
Rare Disease Film Festival Highlights Patient and Researcher Unity
This post was originally published on this site Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly…